vs
Apellis Pharmaceuticals, Inc.（APLS）与SIMMONS FIRST NATIONAL CORP（SFNC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是SIMMONS FIRST NATIONAL CORP的1.0倍（$199.9M vs $197.3M），SIMMONS FIRST NATIONAL CORP同比增速更快（19.6% vs -5.9%），SIMMONS FIRST NATIONAL CORP自由现金流更多（$411.4M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 0.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
西蒙斯第一国民公司是一家银行控股企业，旗下核心子公司西蒙斯银行的业务覆盖阿肯色州、堪萨斯州、密苏里州、俄克拉荷马州、田纳西州及得克萨斯州，为当地客户提供各类银行相关金融服务。
APLS vs SFNC — 直观对比
营收规模更大
APLS
是对方的1.0倍
$197.3M
营收增速更快
SFNC
高出25.6%
-5.9%
自由现金流更多
SFNC
多$425.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $197.3M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 19.6% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSFNC
| Q4 25 | $199.9M | $197.3M | ||
| Q3 25 | $458.6M | $186.7M | ||
| Q2 25 | $178.5M | $214.2M | ||
| Q1 25 | $166.8M | $209.6M | ||
| Q4 24 | $212.5M | $208.5M | ||
| Q3 24 | $196.8M | $174.8M | ||
| Q2 24 | $199.7M | $197.2M | ||
| Q1 24 | $172.3M | $195.1M |
净利润APLSSFNC
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-562.8M | ||
| Q2 25 | $-42.2M | $54.8M | ||
| Q1 25 | $-92.2M | $32.4M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $24.7M | ||
| Q2 24 | $-37.7M | $40.8M | ||
| Q1 24 | $-66.4M | $38.9M |
营业利润率APLSSFNC
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — | ||
| Q1 24 | -36.0% | — |
净利率APLSSFNC
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -301.5% | ||
| Q2 25 | -23.6% | 25.6% | ||
| Q1 25 | -55.3% | 15.5% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 14.1% | ||
| Q2 24 | -18.9% | 20.7% | ||
| Q1 24 | -38.5% | 19.9% |
每股收益（稀释后）APLSSFNC
| Q4 25 | $-0.40 | $0.36 | ||
| Q3 25 | $1.67 | $-4.00 | ||
| Q2 25 | $-0.33 | $0.43 | ||
| Q1 25 | $-0.74 | $0.26 | ||
| Q4 24 | $-0.30 | $0.38 | ||
| Q3 24 | $-0.46 | $0.20 | ||
| Q2 24 | $-0.30 | $0.32 | ||
| Q1 24 | $-0.54 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $620.0M |
| 股东权益账面价值 | $370.1M | $3.4B |
| 总资产 | $1.1B | $24.5B |
| 负债/权益比越低杠杆越低 | — | 0.18× |
8季度趋势，按日历期对齐
现金及短期投资APLSSFNC
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSSFNC
| Q4 25 | — | $620.0M | ||
| Q3 25 | — | $667.8M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | $93.1M | $1.2B |
股东权益APLSSFNC
| Q4 25 | $370.1M | $3.4B | ||
| Q3 25 | $401.2M | $3.4B | ||
| Q2 25 | $156.3M | $3.5B | ||
| Q1 25 | $164.2M | $3.5B | ||
| Q4 24 | $228.5M | $3.5B | ||
| Q3 24 | $237.1M | $3.5B | ||
| Q2 24 | $264.3M | $3.5B | ||
| Q1 24 | $266.7M | $3.4B |
总资产APLSSFNC
| Q4 25 | $1.1B | $24.5B | ||
| Q3 25 | $1.1B | $24.2B | ||
| Q2 25 | $821.4M | $26.7B | ||
| Q1 25 | $807.3M | $26.8B | ||
| Q4 24 | $885.1M | $26.9B | ||
| Q3 24 | $901.9M | $27.3B | ||
| Q2 24 | $904.5M | $27.4B | ||
| Q1 24 | $831.9M | $27.4B |
负债/权益比APLSSFNC
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | 0.35× | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $449.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $411.4M |
| 自由现金流率自由现金流/营收 | -7.1% | 208.5% |
| 资本支出强度资本支出/营收 | 0.1% | 19.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $717.0M |
8季度趋势，按日历期对齐
经营现金流APLSSFNC
| Q4 25 | $-14.2M | $449.5M | ||
| Q3 25 | $108.5M | $223.4M | ||
| Q2 25 | $4.4M | $77.6M | ||
| Q1 25 | $-53.4M | $32.8M | ||
| Q4 24 | $19.4M | $425.9M | ||
| Q3 24 | $34.1M | $199.4M | ||
| Q2 24 | $-8.3M | $86.1M | ||
| Q1 24 | $-133.0M | $57.6M |
自由现金流APLSSFNC
| Q4 25 | $-14.3M | $411.4M | ||
| Q3 25 | $108.3M | $216.7M | ||
| Q2 25 | $4.4M | $66.3M | ||
| Q1 25 | $-53.4M | $22.6M | ||
| Q4 24 | $19.3M | $380.4M | ||
| Q3 24 | — | $187.7M | ||
| Q2 24 | $-8.4M | $72.7M | ||
| Q1 24 | $-133.3M | $47.7M |
自由现金流率APLSSFNC
| Q4 25 | -7.1% | 208.5% | ||
| Q3 25 | 23.6% | 116.1% | ||
| Q2 25 | 2.5% | 31.0% | ||
| Q1 25 | -32.0% | 10.8% | ||
| Q4 24 | 9.1% | 182.5% | ||
| Q3 24 | — | 107.4% | ||
| Q2 24 | -4.2% | 36.9% | ||
| Q1 24 | -77.3% | 24.5% |
资本支出强度APLSSFNC
| Q4 25 | 0.1% | 19.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 5.3% | ||
| Q1 25 | 0.0% | 4.8% | ||
| Q4 24 | 0.0% | 21.8% | ||
| Q3 24 | 0.0% | 6.7% | ||
| Q2 24 | 0.0% | 6.8% | ||
| Q1 24 | 0.2% | 5.0% |
现金转化率APLSSFNC
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.06× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | 1.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SFNC
暂无分部数据
